High Sensitivity ECG Device Screens for Heart Disease
|
By HospiMedica International staff writers Posted on 20 Sep 2017 |
|
Image: MyoVista provides detailed visualization of energy distribution during the cardiac cycle (Photo courtesy of HeartSciences).
A low-cost electrocardiograph (ECG) screening device uses advanced signal processing technology to improve the early detection of heart disease.
The MyoVista high sensitivity electrocardiograph (hsECG) testing device, a product of HeartSciences (Westlake, TX, USA), provides clinicians with a detailed visualization of the electrical and structural function of the heart by analyzing energy distribution during the cardiac cycle. Analysis is based on continuous wavelet transform (CWT) signal processing technology, an advanced algorithm that has also revolutionized other early detection and predictive accuracy applications, such as weather forecasting.
MyoVista hsECG uses the same 12-lead, at-rest testing protocol as traditional ECG devices, but beyond conventional ECG interpretive analysis and tracingd, it can also provide unique informatics that can help identify cardiac dysfunction related to coronary artery disease (CAD), structural disease, and arrhythmia. During a 200-patient validation trial, the device detected left ventricular dysfunction in the diastolic phase of the cardiac cycle with 88% sensitivity and 87% specificity. MyoVista hsECG has received the European Community CE mark of approval.
“The application of advanced signal processing technology can assist in closing the diagnostic gap by providing a low-cost, front-line tool which can assist in the early detection of cardiac dysfunction,” said Partho Sengupta, MD, lead investigator of the MyoVista clinical trial and chief of cardiology at West Virginia University (Morgantown, USA). “High sensitivity ECG technology holds significant promise for improving the detection of heart disease.”
“It makes sense to use advanced signal processing to create a modern, low-cost, front-line tool to detect heart disease,” said Mark Hilz, CEO of HeartSciences. “While MyoVista represents a first-of-its-kind application to electrocardiographic testing, advanced signal processing has already enabled key imaging technologies such as computed tomography scans, magnetic resonance imaging, Doppler echo-cardiography, and positron emission tomography scans.”
ECG technology, which functions essentially the same way as when first introduced in 1903, is the front-line screening tool currently used by physicians to detect heart disease. But conventional resting ECG technology detects CAD less than 50% of the time, which leaves a large number of patients who have heart disease undiagnosed. As a result, current healthcare guidance does not recommend use of ECG testing on asymptomatic patients.
Related Links:
HeartSciences
West Virginia University
The MyoVista high sensitivity electrocardiograph (hsECG) testing device, a product of HeartSciences (Westlake, TX, USA), provides clinicians with a detailed visualization of the electrical and structural function of the heart by analyzing energy distribution during the cardiac cycle. Analysis is based on continuous wavelet transform (CWT) signal processing technology, an advanced algorithm that has also revolutionized other early detection and predictive accuracy applications, such as weather forecasting.
MyoVista hsECG uses the same 12-lead, at-rest testing protocol as traditional ECG devices, but beyond conventional ECG interpretive analysis and tracingd, it can also provide unique informatics that can help identify cardiac dysfunction related to coronary artery disease (CAD), structural disease, and arrhythmia. During a 200-patient validation trial, the device detected left ventricular dysfunction in the diastolic phase of the cardiac cycle with 88% sensitivity and 87% specificity. MyoVista hsECG has received the European Community CE mark of approval.
“The application of advanced signal processing technology can assist in closing the diagnostic gap by providing a low-cost, front-line tool which can assist in the early detection of cardiac dysfunction,” said Partho Sengupta, MD, lead investigator of the MyoVista clinical trial and chief of cardiology at West Virginia University (Morgantown, USA). “High sensitivity ECG technology holds significant promise for improving the detection of heart disease.”
“It makes sense to use advanced signal processing to create a modern, low-cost, front-line tool to detect heart disease,” said Mark Hilz, CEO of HeartSciences. “While MyoVista represents a first-of-its-kind application to electrocardiographic testing, advanced signal processing has already enabled key imaging technologies such as computed tomography scans, magnetic resonance imaging, Doppler echo-cardiography, and positron emission tomography scans.”
ECG technology, which functions essentially the same way as when first introduced in 1903, is the front-line screening tool currently used by physicians to detect heart disease. But conventional resting ECG technology detects CAD less than 50% of the time, which leaves a large number of patients who have heart disease undiagnosed. As a result, current healthcare guidance does not recommend use of ECG testing on asymptomatic patients.
Related Links:
HeartSciences
West Virginia University
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Pediatric Mask
Respire SOFT
New
Gas Analyzer
GE SAM
Latest Critical Care News
- Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
Channels
Artificial Intelligence
view channel
AI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
Surgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
